aap Implantate AG / aap Implantate AG launches new company website . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
aap Implantate AG (XETRA: AAQ.DE) today announced the launch of a new company website. The website can be accessed at www.aap.de.
The updated website includes a streamlined user-interface and is designed to be more user-friendly. It includes all of the essential company information for customers, investors and potential shareholders. The main focus of the website is in the Investors and Products sections. In the products section, all of aap's Trauma and Biomaterials products are presented along with their specific characteristics and advantages. For LOQTEQ(R), a special navigation aid, the "LOQTEQ(R)-man", was created to educate visitors on this innovative line of trauma products. In the Investors section, standard company information is presented, including the aap's annual and quarterly financial statements, real-time stock price information and key indicators, press releases and ad hoc announcements, presentations, analyses, the financial calendar as well as items concerning the annual general meeting and corporate governance.
The website is available in two languages, German and English, with plans to additional language options as the Company continues to build its presence in international markets.
Biense Visser, CEO of aap Implantate AG: "Over the last few years, we have successfully focused aap's business on the Company's core competencies in trauma products and biomaterials, while also driving growth in international markets. The launch of our updated corporate website reflects our excellent progress with these initiatives and aap's enhanced position in the market. The new website is easy to navigate and provides a clear overview of the Company, which is important as we secure interest from potential customers, partners and investors around the world."
This release contains forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.
aap Implantate AG (ISIN DE0005066609)
- Prime Standard/Regulated Market - All German stock markets -
aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit http://www.aap.de/ www.aap.de, or download the Company's investor relations app from the https://itunes.apple.com/app/aap-implantate-ag-ir/id572962043?mt=8 Apple's App Store or https://play.google.com/store/apps/details?id=com.theirapp.aaq Google Play.
For inquiries please contact:
aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, email@example.com
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: aap Implantate AG via Thomson Reuters ONE
--- End of Message ---
aap Implantate AG
Lorenzweg 5 Berlin Germany
WKN: 506660;ISIN: DE0005066609;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
www.aap.de (END) Dow Jones Newswires
April 25, 2013 04:36 ET (08:36 GMT)- - 04 36 AM EDT 04-25-13
|Newron-Aktie gegen Trend fest: Safinamide erhält FDA-Zulassung für Parkinson-Krankheit|
|Meyer Burger-Aktie gibt ab: 2016 hoher zweistelliger Millionen-Reinverlust|
|Apple überarbeitet das iPad-Angebot - Aktie steigt auf Allzeithoch|
|Trump fällt in Reichenliste zurück|
|SMI schliesst schwächer -- DAX beendet Handel mit Verlust -- Dow Jones im Minus|
|Partners Group-Aktie springt an: Ertrag und Gewinn 2016 gesteigert|
|SMI schliesst tiefer -- DAX beendet Handel mit Abschlägen -- Dow Jones zum Schluss unverändert|
|Novartis-Aktien fallen nach enttäuschenden Daten zu Serelaxin zurück|
|Neuer Tesla-Konkurrent könnte Musks E-Autos in den Schatten stellen|
|Roche, Novartis & Co. im Minus - Trump twittert wieder|